Cancers

SJR Rank #2,720H-index: 182SJR: 1.410Best quartile: Q1Open AccessAPC: US$3,499
Journal website: aims, scope and author guidelines
Publisher

Multidisciplinary Digital Publishing Institute (MDPI)

Country

Switzerland

Type

journal

SJR by Edition

2022202500.40.81.21.6

Subject Categories

  • OncologyQ1
  • Cancer ResearchQ2

Areas: Biochemistry, Genetics and Molecular Biology · Medicine

Most published research topics

Cancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsCancer Cells and MetastasisPancreatic and Hepatic Oncology ResearchRadiomics and Machine Learning in Medical ImagingGlioma Diagnosis and TreatmentCancer, Hypoxia, and MetabolismHepatocellular Carcinoma Treatment and PrognosisEpigenetics and DNA MethylationImmunotherapy and Immune Responses

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs0450090001350018000

Documents per Year

2022202502000400060008000

Detailed Information

ISSN

2072-6694

SJR Best Quartile

Q1

Region

Western Europe

Citations per Document (2 years)

4.88

References per Document

66.54

Coverage

2009-2026

Scope

Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes article types including Research Papers, Reviews, Editorials, Communications, etc. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. The full experimental details must be provided so that the results can be reproduced. There is, in addition, a unique feature of this journal: we accept studies showing meaningful but negative results. While there are many journals that focus on cancer studies, none of them actively accepts negative results. As a result, most negative data end up not being in the public domain even if the data were meaningfully negative and the study well designed. By accepting those negative results, our journal encourages scientists to share those data so that they would not need to repeat the experiments that somebody else has already done. We publish high-quality articles including basic, translational, and clinical studies on all tumor types.

Metrics from SCImago Journal Rank 2025. View on SCImago